IHT Wealth Management LLC Sells 6,725 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

IHT Wealth Management LLC reduced its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 2.4% during the 4th quarter, HoldingsChannel reports. The fund owned 270,160 shares of the company’s stock after selling 6,725 shares during the period. IHT Wealth Management LLC’s holdings in Xeris Biopharma were worth $916,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in shares of Xeris Biopharma by 87.8% in the 3rd quarter. Barclays PLC now owns 324,472 shares of the company’s stock worth $925,000 after acquiring an additional 151,685 shares during the last quarter. Geode Capital Management LLC raised its position in Xeris Biopharma by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after purchasing an additional 93,091 shares during the period. Principal Financial Group Inc. lifted its stake in Xeris Biopharma by 30.3% in the third quarter. Principal Financial Group Inc. now owns 102,469 shares of the company’s stock worth $292,000 after purchasing an additional 23,843 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Xeris Biopharma by 20.8% during the third quarter. JPMorgan Chase & Co. now owns 391,960 shares of the company’s stock valued at $1,117,000 after buying an additional 67,557 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Xeris Biopharma by 57.3% during the fourth quarter. SG Americas Securities LLC now owns 94,671 shares of the company’s stock valued at $321,000 after buying an additional 34,469 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.56% of the stock is currently owned by insiders.

Xeris Biopharma Stock Performance

NASDAQ:XERS opened at $4.28 on Friday. The firm has a 50-day simple moving average of $4.49 and a 200-day simple moving average of $3.73. Xeris Biopharma Holdings, Inc. has a one year low of $1.69 and a one year high of $6.07. The firm has a market cap of $658.86 million, a P/E ratio of -9.51 and a beta of 1.37.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on XERS. Leerink Partners boosted their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, March 7th. Piper Sandler restated a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum boosted their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.10.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.